Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783403 · ClinicalTrials.gov registry record · Phase 1
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT03783403: Clinical Trial Phase 1 study, sponsored by Celgene.
NCT03783403 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 206 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (243% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03783403, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.
Interventions
- DRUG Rituximab
- DRUG Cetuximab
- DRUG CC-95251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 1 |
Why NCT03783403 stopped before completion
NCT03783403 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (243% higher).
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT03783403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03783403 about?
NCT03783403 is a clinical study titled "A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers". The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.
What is the current status of trial NCT03783403?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2019-03-01. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT03783403?
The interventions under investigation include: Rituximab (DRUG), Cetuximab (DRUG), CC-95251 (DRUG).
Who is sponsoring clinical trial NCT03783403?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03783403's enrollment target sits among peer trials
206 253rd of 2000 higher than 1,748 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI